MedinCell SA (FR:MEDCL)
:MEDCL
Top Page
MedinCell SA
(MEDCL)
Select Model
Select Model
Rating:49Neutral
Price Target:
€20.00
▼(-13.42% Downside)
Action:UpgradedDate:01/29/26
The score is held back primarily by weak financial performance (large losses and negative equity/leverage risk) and a soft technical setup (below key moving averages with subdued momentum). These are partly offset by a positive earnings-call outlook highlighting regulatory progress, partner-driven commercial growth (UZEDY), and pipeline/milestone potential.
Positive Factors
Strong revenue growth
Sustained top-line expansion near 100% indicates strong commercial traction and partnership-driven royalties (UZEDY). Durable revenue growth improves runway and validates the BEPO® platform's market fit, supporting continued investment in pipeline and de-risking long-term cash generation.
Negative Factors
High leverage and negative equity
Liabilities exceeding assets and significant leverage are structural red flags that constrain strategic flexibility. Negative equity distorts metrics (ROE) and increases refinancing and covenant risk, making long‑term funding and M&A optionality more expensive or uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Sustained top-line expansion near 100% indicates strong commercial traction and partnership-driven royalties (UZEDY). Durable revenue growth improves runway and validates the BEPO® platform's market fit, supporting continued investment in pipeline and de-risking long-term cash generation.
Read all positive factors
MedinCell SA (MEDCL) vs. iShares MSCI France ETF (EWQ)
Market Cap
€829.37M
Dividend YieldN/A
Average Volume (3M)179.66K
Price to Earnings (P/E)―
Beta (1Y)0.98
Revenue Growth166.31%
EPS Growth43.80%
CountryFR
Employees131
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.49
Shares Outstanding35,907,510
10 Day Avg. Volume204,359
30 Day Avg. Volume179,664
Financial Highlights & Ratios
PEG Ratio0.80
Price to Book (P/B)-25.60
Price to Sales (P/S)16.41
P/FCF Ratio23.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€36.60Price Target Upside58.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.27
Revenue Forecast (FY)€51.54M
MedinCell SA Business Overview & Revenue Model
Company Description
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active phar...
How the Company Makes Money
MedinCell primarily makes money by partnering its BEPO® long-acting injectable technology with other pharmaceutical companies’ active ingredients and by participating in the downstream economics of partnered products. Key revenue streams include: ...
MedinCell SA Earnings Call Summary
Earnings Call Date:Dec 09, 2025
(Q2-2026)
| % Change Since: |
Next Earnings Date:Jun 16, 2026
Earnings Call Sentiment Positive
The earnings call presented a generally positive outlook for MedinCell, emphasizing significant milestones such as the FDA filing of Olanzapine LAI and robust growth in UZEDY sales. Despite some financial challenges due to currency fluctuations and non-cash impacts, the company's strategic initiatives and pipeline expansions suggest a promising future.Positive Updates
Olanzapine LAI FDA Filing
Teva filed the Olanzapine LAI at the FDA, with a potential approval expected in Q4 2026. This filing is seen as a major milestone for MedinCell and is expected to significantly accelerate growth.
Negative Updates
Impact of Weak U.S. Dollar
The weak U.S. dollar negatively impacted MedinCell's financial results, contributing to a 13% operating loss improvement, but potentially delaying return to profitability.
Read all updates
Q2-2026 Updates
Positive
Negative
Olanzapine LAI FDA Filing
Teva filed the Olanzapine LAI at the FDA, with a potential approval expected in Q4 2026. This filing is seen as a major milestone for MedinCell and is expected to significantly accelerate growth.
Read all positive updates
Company Guidance
During the call, MedinCell provided comprehensive guidance on its strategic growth, focusing on its key products and future prospects. They highlighted the recent filing of Olanzapine LAI with the FDA, with an expected approval by Q4 2026, which could bring a $4 million milestone upon approval and $105 million in commercial milestones. MedinCell's partner, Teva, confirmed guidance for UZEDY sales of $190-$200 million in 2025, marking significant progress with a 65% sales increase in Q3 2025 compared to the previous year. They also discussed a strategic alliance with AbbVie, with the first program ready to launch into Phase I in 2026, potentially leading to $315 million in milestones and low double-digit royalties. Additionally, MedinCell's financials showed a 50% revenue increase for the half-year ending September 30, 2025, driven by UZEDY royalties and R&D partnerships, with operating expenses rising 22% due to pipeline maturation. The company also maintains a robust cash position, providing visibility for at least two years. Looking ahead, MedinCell aims to maintain its technological leadership and expand its pipeline with multiple undisclosed programs in development across more than five therapeutic areas.MedinCell SA Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
30
Negative
Cash Flow
50
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.71M | 25.54M | 9.16M | 9.94M | 4.09M | 8.19M |
| Gross Profit | 16.11M | 25.54M | 9.16M | 9.94M | 4.09M | 6.74M |
| EBITDA | -18.74M | -11.20M | -18.61M | -26.41M | -21.45M | -15.38M |
| Net Income | -19.95M | -18.44M | -25.04M | -32.01M | -24.81M | -19.02M |
Balance Sheet | ||||||
| Total Assets | 74.58M | 90.45M | 36.95M | 29.34M | 44.30M | 63.61M |
| Cash, Cash Equivalents and Short-Term Investments | 53.50M | 71.90M | 19.46M | 6.47M | 26.59M | 49.87M |
| Total Debt | 58.27M | 58.76M | 58.96M | 57.71M | 47.49M | 43.34M |
| Total Liabilities | 105.21M | 106.82M | 77.77M | 71.63M | 57.67M | 54.69M |
| Stockholders Equity | -30.63M | -16.37M | -40.82M | -42.29M | -13.37M | 8.92M |
Cash Flow | ||||||
| Free Cash Flow | -17.88M | 17.80M | -13.11M | -22.03M | -23.34M | -12.96M |
| Operating Cash Flow | -17.10M | 19.46M | -11.92M | -21.00M | -21.36M | -12.14M |
| Investing Cash Flow | 685.00K | -13.21M | -613.00K | 1.30M | -316.00K | -1.06M |
| Financing Cash Flow | 34.55M | 33.32M | 25.53M | 1.56M | -800.00K | 47.92M |
MedinCell SA Technical Analysis
Neutral
23.10
Price Trends
23.12
Negative
25.13
Negative
23.56
Negative
Market Momentum
-0.13
Negative
55.34
Neutral
89.15
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:MEDCL, the sentiment is Neutral. The current price of 23.1 is above the 20-day moving average (MA) of 21.61, below the 50-day MA of 23.12, and below the 200-day MA of 23.56, indicating a neutral trend. The MACD of -0.13 indicates Negative momentum. The RSI at 55.34 is Neutral, neither overbought nor oversold. The STOCH value of 89.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:MEDCL.
MedinCell SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | €1.33B | -9.10 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | €829.37M | -12.22 | ― | ― | 166.31% | 43.80% | |
47 Neutral | €979.98M | -0.41 | ― | ― | -12.84% | -81.94% | |
46 Neutral | €8.04B | -24.91 | ― | ― | ― | 18.52% | |
46 Neutral | €466.36M | -5.43 | -58.93% | ― | 13.48% | -1299.09% | |
45 Neutral | €1.01B | -3.62 | -241.12% | ― | ― | 3.09% |
* Healthcare Sector Average
FR:MEDCL
MedinCell SA
23.10
10.04
76.88%
FR:ABVX
Abivax SA
101.40
96.55
1990.72%
FR:DBV
DBV Technologies
3.64
2.35
183.10%
FR:IVA
Inventiva
4.72
2.00
73.53%
FR:NANO
Nanobiotix
27.40
24.45
828.81%
FR:VLA
Valneva
2.71
-0.08
-3.01%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.